RAD140, a Selective Androgen Receptor Modulator (SARM), is associated with potential suppression of natural testosterone production. Here's a structured summary of its effects:
1.Mechanism of Suppression:
RAD140 binds to androgen receptors, mimicking natural androgens. This can signal the hypothalamus and pituitary gland to reduce the release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), critical for testosterone production. The body may perceive sufficient androgen activity, leading to downregulation of the hypothalamic-pituitary-gonadal (HPG) axis.
2.Evidence and Reports:
Preclinical Studies: Limited animal and in vitro studies suggest SARMs like RAD140 can suppress testosterone, though human data is scarce.
Anecdotal Evidence: Users often report testosterone suppression, particularly with higher doses or prolonged cycles (8+ weeks), noting symptoms like fatigue, low libido, and mood changes. Post-cycle therapy (PCT) with drugs like Clomid is common to restore natural levels.
3.Dose and Duration Dependence:
Suppression severity may correlate with dosage and cycle length. Shorter cycles (4-6 weeks) at lower doses might minimize impact, while longer/higher-dose use increases suppression risk.
4.Recovery and PCT:
Testosterone levels may recover post-cycle, but recovery time varies. Some individuals resume normal function within weeks, while others require PCT to stimulate LH/FSH production.
5.Considerations:
Lack of FDA Approval: RAD140 is not approved for human use, so long-term safety data is absent.
Individual Variability: Responses differ based on genetics, age, and health status.
Conclusion: RAD140 likely suppresses testosterone by disrupting the HPG axis, akin to steroids but potentially with less severity. Users should approach its use cautiously, considering risks and consulting healthcare professionals.
